Breaking News
August 21, 2018 - Clinical Trials Balance Out Urban, Rural Cancer Survival Rates
August 21, 2018 - New target found for treating thoracic aortic aneurysm
August 21, 2018 - Tumor cells’ ‘tells’ may allow some cancer patients to dodge unnecessary chemotherapy
August 21, 2018 - Dehydration changes shape and activity of the brain, reduces task performance
August 21, 2018 - Scientists discover peptides that can be used as new antibiotic candidates
August 21, 2018 - ‘Compulsivity circuit’ may drive alcohol-seeking behavior in heavy drinkers
August 21, 2018 - Type 2 diabetes on the rise among youngsters
August 21, 2018 - Genital warts may promote HIV sexual transmission
August 21, 2018 - Drop the C-word to reduce anxiety and overtreatment, say experts
August 21, 2018 - Kid-friendly MRI equipment has advantages for grown-ups, too
August 21, 2018 - Scleroderma Foundation names Tulane professor as ‘Doctor of the Year’
August 21, 2018 - Chagas disease causes chronic heart disease and has spread outside of Latin America
August 21, 2018 - FDA stirs debate by approving ‘natural’ app
August 21, 2018 - Clay may help fight disease-causing bacteria in wounds
August 21, 2018 - Emerging field of diabetology could address growing crisis in health care
August 21, 2018 - Experts examine stool protein biomarkers that indicate inflammatory bowel disease
August 21, 2018 - Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS
August 21, 2018 - Ovarian cancer cells hoard iron to fuel growth
August 21, 2018 - New Biodesign fellows will focus on vision care
August 21, 2018 - Prenatal DDT Exposure Associated with Greater Risk of Autism
August 21, 2018 - Cruciferous vegetables found to protect against colon cancer in mice
August 21, 2018 - New studies point to a promising future for bioengineered teeth
August 21, 2018 - ACR expresses concerns on step therapy in a recent meeting with HSS Secretary
August 21, 2018 - Gene therapy with telomerase does not increase cancer risk, study shows
August 21, 2018 - Ovarian cancer screening influenced by unconscious bias, study shows
August 21, 2018 - Scientists report novel gene therapy that halts vision loss in canine model of blinding disease
August 21, 2018 - RxBenefits introduces new tailored and flexible approach to managing hospital pharmacy benefits
August 21, 2018 - Motif Bio Announces FDA Acceptance of New Drug Application With Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections
August 21, 2018 - Google Glass helps kids with autism read facial expressions, study finds
August 21, 2018 - Thrombospondin-1 contributes to development of aortic aneurysm in mice and humans, study finds
August 21, 2018 - National Foundation for Cancer Research receives Safeway Foundation grant
August 21, 2018 - Protein aggregation in neurons linked to gene regulation in Huntington’s disease
August 21, 2018 - Aravive Biologics gains Fast Track Designation for AVB-S6-500 from U.S. FDA
August 21, 2018 - FDA Approves Opdivo (nivolumab) for Certain Patients with Previously Treated Small Cell Lung Cancer
August 21, 2018 - Success of blood test for autism affirmed
August 21, 2018 - Diabetic patients with disrupted sleep may need more time to heal their wounds
August 21, 2018 - AADE honors six educators for achievements in diabetes education
August 21, 2018 - Scientists find two molecules that may combat cancer and chronic infections
August 21, 2018 - Two Strategies for Preventing Diabetes in Minority Patients
August 21, 2018 - Living as a Gallbladder Cancer Survivor
August 21, 2018 - Can we predict the long-term outcome of boys with ADHD?
August 21, 2018 - GBCA creates model for developing scientist-advocate collaborations in cancer research
August 21, 2018 - Healthy diet could help promote healthy cellular aging in women
August 21, 2018 - Researchers develop gene expression predictor for immunotherapy response in melanoma
August 21, 2018 - Genome sequences of ape parasites provide insights on origin and early evolution of malaria
August 21, 2018 - MDI Biological Laboratory introduces Morris Scientific Discovery Fund for eligible research programs
August 21, 2018 - Pediatric brain tumor patients who undergo radiation less likely to recall recently experienced events
August 21, 2018 - Micro-flow model reveals complex interactions between the brain’s blood vessels and nerve cells
August 21, 2018 - Study investigates impact of osteoporosis on risk of developing dementia
August 21, 2018 - Federal method fails to detect most stores that sell cigarettes to minors
August 21, 2018 - Workers in open office seating have less stress than those in private offices and cubicles
August 21, 2018 - 1 in 4 in U.S. Has a Disability, CDC Reports
August 21, 2018 - Studies provide new insights into the role of sleep in chronic pain
August 21, 2018 - Study shows that rogue proteins may underlie some ALS and frontotemporal dementia cases
August 21, 2018 - Elevated LDL cholesterol levels linked to higher risk of CVD death in young, healthy people
August 21, 2018 - Measles cases on the rise in Europe
August 21, 2018 - CURE Media Group welcomes CancerCare to Strategic Alliance Partnership Program
August 21, 2018 - Blood management program associated with fewer transfusions in orthopedic patients
August 21, 2018 - Researchers create the world’s first artificial retina
August 21, 2018 - Yale researchers identify racial disparities in prescribing opioids for chronic pain
August 21, 2018 - BOOST-3 clinical trial aims to improve outcomes for severe TBI patients
August 21, 2018 - New study highlights Alzheimer’s herpes link, experts say
August 21, 2018 - Airline crew don’t have significantly elevated risk of thyroid cancer, new study finds
August 21, 2018 - States leverage federal funds to help insurers lower premiums
August 21, 2018 - New badge course explores research around skeletal muscle as an endocrine organ
August 21, 2018 - TG Therapeutics Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in Multiple Sclerosis
August 21, 2018 - Increased levels of human herpesvirus ID’d in Alzheimer’s
August 21, 2018 - To help patients quash pain, researcher develops practical guide for health care providers
August 20, 2018 - Medicine on the front line to be presented at Medical Innovation 2018
August 20, 2018 - Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody
August 20, 2018 - The man who sold America on vitamin D — and profited in the process
August 20, 2018 - Finding the light in antimicrobials
August 20, 2018 - Unique pain program helps surgical patients wean off opioids safely and effectively
August 20, 2018 - Strawberries could mitigate colonic inflammation
August 20, 2018 - FDA Accepts New Drug Application (NDA) to Review Midazolam Nasal Spray, an Investigational Product for the Acute Treatment of Seizure Clusters
August 20, 2018 - Using Facebook to help young adults quit smoking
August 20, 2018 - ‘Liquid biopsy’ predicts lymphoma therapy success within days | News Center
August 20, 2018 - 5 Questions with Jordan Orange, Chair of Pediatrics
August 20, 2018 - New assay may help improve both sarcoma diagnosis and treatment
August 20, 2018 - New information on the brain regions related to metacognition, tactile sense
Double-blind study shows HIV vaccine not effective in viral suppression

Double-blind study shows HIV vaccine not effective in viral suppression

image_pdfDownload PDFimage_print
Credit: National Cancer Institute

(Medical Xpress)—A large team of researchers from the U.S. and Canada has conducted a randomized double-blind study of the effectiveness of an HIV vaccine and has found it to be ineffective in suppressing the virus. In their paper published in Science Translational Medicine, the group describes the study, what they found and why they believe their work has provided the medical research community a valuable lesson on the importance of placebo-controlled studies. Michael Nelson with Walter Reed Army Institute of Research offers a FOCUS piece on the work done by the team in the same journal issue.

A lot of research has gone into curing people infected with HIV, but that goal has still not been achieved. In the meantime, antiretroviral therapy (ART) drugs allow people infected with the virus to live an almost normal existence. But the goal of developing a vaccine remains. One approach has been to provide a two-stage attack, injecting patients first with a HIV multi-antigen and a DNA plasmid encoding human interleukin proteins and then following up with a booster containing a viral vector. The idea behind this approach is to nudge the immune system into learning how to combat the virus so that ART drugs are no longer needed. But, the approach has not been proven. In this new effort, the research team conducted a study designed to test the effectiveness of the vaccine.

The study consisted of enlisting the assistance of 30 early-stage patients (one dropped out) with HIV infections who were already being treated with ARTs and assigning them to one of two groups—14 patients got the vaccine while 15 got a placebo. Injections took place at 0, 4, 12, 24, 36 and 48 weeks. ART drug administration was halted for all of the volunteers starting at week 56 and lasting until week 72. All of the volunteers were tested regularly throughout the study for viral loads, a measure of how well the body, along with ARTs and/or the vaccine, was working to suppress the virus.

The researchers report that they found no measurable increase in effectiveness in any of the volunteers who were given the vaccine. They also report that they were surprised to see that four of the volunteers who had received the placebo had lower than normal viral loads for a short time. This finding was particularly important, the researchers note, because it showed that if the study not been conducted with placebos, the results would have showed that the vaccine had worked to a limited extent. And that, Nelson notes, is the real lesson learned from this study.


Explore further:
Trials show inactivated Zika virus vaccine is safe and immunogenic

More information:
Michael C. Sneller et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aan8848

Abstract

Despite substantial clinical benefits, complete eradication of HIV has not been possible using antiretroviral therapy (ART) alone. Strategies that can either eliminate persistent viral reservoirs or boost host immunity to prevent rebound of virus from these reservoirs after discontinuation of ART are needed; one possibility is therapeutic vaccination. We report the results of a randomized, placebo-controlled trial of a therapeutic vaccine regimen in patients in whom ART was initiated during the early stage of HIV infection and whose immune system was anticipated to be relatively intact. The objectives of our study were to determine whether the vaccine was safe and could induce an immune response that would maintain suppression of plasma viremia after discontinuation of ART. Vaccinations were well tolerated with no serious adverse events but produced only modest augmentation of existing HIV-specific CD4+ T cell responses, with little augmentation of CD8+ T cell responses. Compared with placebo, the vaccination regimen had no significant effect on the kinetics or magnitude of viral rebound after interruption of ART and no impact on the size of the HIV reservoir in the CD4+ T cell compartment. Notably, 26% of subjects in the placebo arm exhibited sustained suppression of viremia (

Journal reference:
Science Translational Medicine

Tagged with:

About author

Related Articles